Compare GROW & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GROW | CELU |
|---|---|---|
| Founded | 1968 | 2016 |
| Country | United States | United States |
| Employees | N/A | 123 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7M | 35.2M |
| IPO Year | 1995 | N/A |
| Metric | GROW | CELU |
|---|---|---|
| Price | $2.72 | $0.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 23.8K | ★ 147.2K |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.53% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $23,850,609.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $76.00 |
| P/E Ratio | $10.04 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.23 | $0.71 |
| 52 Week High | $3.65 | $4.35 |
| Indicator | GROW | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 51.05 | 39.14 |
| Support Level | $2.51 | $0.71 |
| Resistance Level | $2.74 | $1.46 |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 52.22 | 23.73 |
US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.